EX-10.12 9 d892618dex1012.htm COLLABORATIVE DEVELOPMENT AGREEMENT (GENETHON) * Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant...Collaborative Development Agreement • May 5th, 2020 • England and Wales
Contract Type FiledMay 5th, 2020 JurisdictionThis COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00Collaborative Development Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledJanuary 4th, 2016 Company Industry JurisdictionThis COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00Collaborative Development Agreement • December 18th, 2015 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledDecember 18th, 2015 Company Industry JurisdictionThis COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).